Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

20 ta ish

Ish: The Role of Chemotherapy in Triple Negative Breast Cancer

  1. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

    Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard +7

    Maqola20075 iqtibos
    ABI

  2. Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy

    Brian D. Lehmann, Jennifer A. Pietenpol, Antoinette R. Tan

    Maqola20154 iqtibos
    ABI

  3. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar, Lijun Zhang, Michael Untch +34

    Sharh maqola20144 iqtibos
    ABI

  4. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

    Brian D. Lehmann, Joshua A. Bauer, Xi Chen +4

    Maqola20114 iqtibos
    ABI

  5. Globocan 2000 : cancer incidence, mortality and prevalence worldwide

    Jacques Ferlay, Paola Pisani, Donald Maxwell Parkin

    Kitob20013 iqtibos
    ABI

  6. Molecular Subtype of Breast Cancer Metastases Significantly Influences Patient Post-Relapse Survival

    Nicholas P. Tobin, J. Chuck Harrell, Søren Brage +5

    Maqola20143 iqtibos
    ABI

  7. Pathological complete response in breast cancer – Authors' reply

    Patricia Cortazar, Charles E. Geyer, Luca Gianni +2

    Boshqa20153 iqtibos
    ABI

  8. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

    Gϋnter von Minckwitz, Michael Untch, Eveline Nüesch +20

    Maqola20103 iqtibos
    ABI

  9. Characteristics of triple-negative breast cancer

    Tim C. de Ruijter, Jürgen Veeck, Joep P.J. de Hoon +2

    Sharh maqola20103 iqtibos
    ABI

  10. Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors

    Valentina Guarneri, Kristine Broglio, Shu‐Wan Kau +8

    Maqola20063 iqtibos
    ABI

  11. Triple-Negative Breast Cancer: An Unmet Medical Need

    Clifford A. Hudis, Luca Gianni

    Sharh maqola20113 iqtibos
    ABI

  12. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

    Thérese Sørlie, Charles M. Perou, Robert Tibshirani +14

    Maqola20013 iqtibos
    ABI

  13. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

    Mark Ayers, W. Fraser Symmans, James Stec +15

    Maqola20043 iqtibos
    ABI

  14. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier, Charles M. Perou, W. Fraser Symmans +13

    Maqola20053 iqtibos
    ABI

  15. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Gabriel N. Hortobágyi

    Maqola20123 iqtibos
    ABI

  16. Triple Negative Breast Cancer Pathologic Diagnosis and Current Chemotherapy Treatment Options

    Bernardo L. Rapoport, Simon Nayler, Georgia Demetriou +2

    Maqola20143 iqtibos
    ABI

  17. Survival in triple-negative breast cancer (TNBC): Evidence from the SEER database 2010-2011.

    Rebecca Dent, Paul N. Mainwaring, Tira J. Tan +4

    Maqola20153 iqtibos
    ABI

  18. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

    Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess +10

    Maqola20233 iqtibos
    ABI

  19. Gene expression profiling predicts clinical outcome of breast cancer

    Laura Van 't Veer, Hongyue Dai, Marc Van De Vijver +67

    Maqola20022 iqtibos
    ABI

  20. Sarlavhasiz

    Boshqa1 iqtibos
    ABI